Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Top Midday Decliners
Oracle (ORCL) plans to raise about $40 billion via debt and equity issuances in fiscal 2027, includi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Atossa Therapeutics Announces $16.5 Million Registered Direct Offering; Stock Down
(RTTNews) - Atossa Therapeutics, Inc. (ATOS) has entered into a securities purchase agreement with institutional investors for a registered direct offering of up to $16.5 million in gross proceeds. The transaction includes an initial $4.5…
Atossa Therapeutics prices up to $16.5M direct offering
* Atossa Therapeutics (ATOS [https://seekingalpha.com/symbol/ATOS]) said [https://seekingalpha.com/pr/20548351-atossa-therapeutics-announces-registered-direct-offering-of-up-to-16_5-million-in-gross] on Thursday it entered into a registere…
Atos Selected by Viasat to Modernize Global Digital Workplace Operations
Atos IT Solutions and Services, Inc. Irving, Texas, USA – Paris, France – May 19, 2026 – Atos, a global leader in AI-powered digital transformation, today announced it has been selected by Viasat, a global leader in satellite communication…
Atossa Gets FDA Rare Pediatric Disease Tag For (Z)-Endoxifen In McCune-Albright Syndrome
(RTTNews) - Atossa Therapeutics, Inc. (ATOS) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females. McCune-Albright Syn…
Insider Trading Fugitive Stuck in China After US Flight Ban
(Bloomberg) -- A fugitive accused of insider trading says he’s trapped in China because the US won’t let him board a plane to Boston to fight the charges against him. The Justice Department isn’t sympathetic, saying he created the problem…
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
Atos IT Solutions and Services, Inc. Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 –Atos, a global leader of AI-powered digital transformation today announced a significan…
Notice of the Annual General Meeting to Approve the 2025 Financial Statements, Scheduled for May 22, 2026, and Changes to the Atos Board of Directors
Press Release Notice of the Annual General Meeting to Approve the 2025 Financial Statements, Scheduled for May 22, 2026, and Changes to the Atos Board of Directors Paris, France - March 27, 2026 Notice of the Annual General Meeting on May…
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22
* Atossa Therapeutics press release [https://seekingalpha.com/pr/20451740-atossa-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-a] (ATOS [https://seekingalpha.com/symbol/ATOS]): FY GAAP EPS of -$4.04 m…
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing…
After-Hours Gainers: ATOS, IBRX, FEMY, FHTX, DARE, TBPH
(RTTNews) - Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment. Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, u…
Atossa Secures FDA Orphan Drug Designation For (Z)-Endoxifen In Duchenne Muscular Dystrophy
(RTTNews) - Atossa Therapeutics, Inc. (ATOS) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dy…
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma
[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner * The U.S. Food and Drug Administration has granted Atossa Therapeutics’ (ATOS) treatment for soft tissue sarcoma orphan drug designation, offering potentia…
New Strong Sell Stocks for Oct. 14th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Antero Resources AR is an independent explorer, primarily engaged in the acquisition and development of natural gas, natural gas liquids and oil resources in the Ap…
Notable Friday Option Activity: SPOT, OUST, WOOF
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Spotify Technology SA (Symbol: SPOT), where a total of 10,997 contracts have traded so far, representing approximately 1.1 million…
Atossa Therapeutics GAAP EPS of -$0.07 misses by $0.01
* Atossa Therapeutics press release [https://seekingalpha.com/pr/20197604-atossa-therapeutics-announces-second-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:ATOS [https://seekingalpha.com/symbol/ATOS]): Q2 GAAP EPS of -$…
European stocks decline after more trade turmoil; U.S. payrolls in focus
Investing.com - European stocks fell Friday as investors digested U.S. President Donald Trump’s fresh levies on imports from dozens of countries as well as more corporate earnings, and the release of key regional inflation data and the wid…
Advanced Authentication Market Outlook Report 2025-2029: Advanced Authentication Market to Surge by USD 75.57 Billion from 2024-2029, Driven by Online Transactions Boom
Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Advanced Authentication Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The advanced authentication market is projected to expand by USD 75.57 billion from 2024 to 2029,…
Atos posts H1 drop in orders and revenue on weak demand, tough market backdrop
Investing.com -- French IT company Atos reported a drop in both revenue and orders for the first half (H1) of the year, citing weak commercial activity in France and a difficult market backdrop. Order intake reached €3.3 billion over the s…
Atos shares climb 4% after reporting stronger half-year liquidity position
Investing.com -- Atos (EPA:ATOS) shares rose 4% on Monday after the company published its estimated half-year liquidity figures, showing a sharp reduction in cash outflows compared with the previous year. For the first half of 2025, the Fr…
France stocks higher at close of trade; CAC 40 up 1.44%
Investing.com – France stocks were higher after the close on Wednesday, as gains in the Healthcare, Financials and Industrials sectors led shares higher. At the close in Paris, the CAC 40 rose 1.44% to hit a new 1-month high, while the SBF…
Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity
Atossa Therapeutics, Inc. (NASDAQ:ATOS) is among the best growth stocks to invest in for the next 5 years. Ascendiant Capital analysts slightly increased the price target for Atossa Therapeutics, Inc. (NASDAQ:ATOS) to $7.50, up from $7.25,…
BofA assesses the impact of foreign tax in budget bill on European software names
Investing.com - European software companies stand to be hit by a section of a massive Republican budget bill which would tax foreign investors in the United States. The proposed tax, included in Section 899 of the package, would slap a pro…
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United…
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for…
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United…
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Compan…
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its st…
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the follow…
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that St…
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That’s because the world of drug development and biotech research tends to rely on big market-mo…
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
By now, you’re well aware of the dangers of trading penny stocks with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here’s what the U.S. SEC says: “Penny stock…
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed. The markets didn’t wait to see if the company can execute the b…
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off. It really comes down…
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look a…